Quick answer
How was melanotan II developed? It came out of a research program on alpha-MSH analogs. In 1980 a [Nle4, D-Phe7] analog was reported to be resistant to serum enzymes and 26 times as potent as alpha-MSH in an adenylate cyclase assay (Sawyer et al., 1980). In 1989 a new class of cyclic melanotropins was designed with quenched dynamics simulations (Al-Obeidi et al., 1989). Between 1992 and 1995 the melanocortin receptors were cloned and characterized, which supplied the receptor-level tools to study such analogs (Mountjoy et al., 1992; Chhajlani et al., 1993; Schiöth et al., 1995). By 1997 a cyclic analog called MTII was being used as a receptor probe in mouse feeding studies (Fan et al., 1997). This page follows that timeline as a research history, with no claims about use. For laboratory research use only; see the MT-2 product page and melanotan II research overview.
A compound's history explains why it is built the way it is and why it keeps showing up in receptor pharmacology. This article is a chronological reading of the primary literature behind melanotan II (MT-2), anchored to what each paper's abstract actually reports. It stays on the early research story, from the hormone to the analog to the receptors, and leaves the later lineage of related analogs to the dedicated PT-141 versus melanotan II comparison. The material is supplied for laboratory research use only; not for human consumption.
Before the analogs: a hormone that darkens frog skin
The starting point was alpha-melanocyte-stimulating hormone, which the 1980 paper describes as a hormone that reversibly darkens frog skins by stimulating melanosome movement within melanophores. That classical bioassay shaped early analog work: the readout was visible and quantitative, and it let chemists compare structures by potency and by how long the effect lasted (Sawyer et al., 1980). The frog-skin assay is the reason the early literature speaks of potency and prolonged activity rather than receptor subtypes; the receptors had not yet been isolated.
The same paper is the source of the observation that triggered the analog program. Heat-alkali exposure of alpha-MSH prolonged its activity, and analysis of the exposed peptide showed partial racemization at the methionine-4 and phenylalanine-7 positions. The authors then built the analogs that mimic those changes directly, and these are the molecules from which the cyclic series later descended. A companion article in this series explains the chemistry of each substitution; here the focus is the sequence of events.
1980: the first superpotent linear analog
Sawyer and colleagues reported that [Nle4]-alpha-MSH reversibly darkened frog skin and also showed prolonged activity after heat-alkali exposure, and that [Nle4, D-Phe7]-alpha-MSH matched the prolonged activity seen with heat-alkali-exposed hormone. The doubly substituted analog resisted degradation by serum enzymes and showed dramatically increased activity in the frog-skin assay, in activation of mouse melanoma adenylate cyclase, and in stimulation of mouse melanoma cell tyrosinase. It was reported as 26 times as potent as alpha-MSH in the adenylate cyclase assay, and the authors suggested it would be an important molecular probe for melanotropin receptors (Sawyer et al., 1980).
Two themes from this paper persist through the rest of the timeline: stability to enzymes as a design goal, and the use of an analog as a probe for receptors that had not yet been cloned. Both explain why a synthetic analog, and not the native hormone, became the reference ligand in later binding work.
1989: cyclization guided by computation
The next documented step is the paper titled "Design of a new class of superpotent cyclic alpha-melanotropins based on quenched dynamics simulations" (Al-Obeidi et al., 1989). No PubMed abstract is indexed for it, so this page cites it for what its title states: that a new class of cyclic melanotropins was designed, that the design was informed by quenched dynamics simulations, and that the compounds were described as superpotent. The title is enough to place the work on the timeline: after the 1980 linear analog came a deliberate attempt to constrain the peptide into a ring.
That attempt matters for MT-2 because the compound's defining feature, as listed on the MT-2 product page, is the cyclic structure Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2 with the formula C50H69N15O9. The lineage from the 1980 substitutions (norleucine, D-phenylalanine) to a lactam-closed ring is visible in the sequence itself.
1992–1995: the receptors catch up
The receptors that these analogs were designed to probe were identified a decade later. Mountjoy and colleagues reported cloning of the murine and human MSH receptors and a human ACTH receptor, defining a subfamily of G-protein-coupled receptors (Mountjoy et al., 1992). In 1993 Chhajlani and colleagues cloned a further human melanocortin receptor, expressed in brain tissue but not in melanoma cells, and showed that when expressed in COS-7 cells it bound radiolabeled [Nle4, D-Phe7]-alpha-MSH with the highest affinity (5.18 nM) among the peptides tested (Chhajlani et al., 1993). The 1980 analog had become the standard radioligand.
In 1995 Schiöth and colleagues characterized three subtypes (MC1, MC3 and MC5) expressed in COS cells and reported Kd values for the radiolabeled analog of 85.1 pM, 396 pM and 5.05 nM, respectively, along with distinct potency orders for the natural melanocortin peptides across subtypes (Schiöth et al., 1995). Cone later reviewed the field, describing five G protein-coupled melanocortin receptors, peptide agonists derived from proopiomelanocortin, and endogenous antagonists, the agouti proteins (Cone, 2006).
| Year | Paper (first author) | What the abstract reports | Why it matters for the analog |
|---|---|---|---|
| 1980 | Sawyer | [Nle4, D-Phe7]-alpha-MSH: enzyme-resistant, 26-fold more potent in adenylate cyclase assay | Defines the design logic of the series |
| 1989 | Al-Obeidi | Title: superpotent cyclic alpha-melanotropins designed with quenched dynamics | Introduces cyclic constraint |
| 1992 | Mountjoy | Cloning of MSH receptors and an ACTH receptor | First molecular receptor targets |
| 1993 | Chhajlani | New human melanocortin receptor binds radiolabeled NDP-MSH at 5.18 nM | Analog becomes a binding tool |
| 1995 | Schiöth | Binding properties of MC1, MC3 and MC5 | Subtype-specific affinity data |
| 1997 | Fan | Cyclic analog MTII used in mouse feeding models | Analog used as an in-vivo receptor probe |
1997: an analog as a probe of central melanocortin signaling
Fan and colleagues used cyclic melanocortin analogs to test a hypothesis about the agouti obesity syndrome. They reported that agouti peptide is an antagonist of the melanocortin-4 receptor as well as MC1-R, identified cyclic analogs that act as potent agonists or antagonists at the neural MC3 and MC4 receptors, and found that intracerebroventricular administration of the agonist MTII inhibited feeding in four mouse models of hyperphagia, an effect blocked by co-administration of the antagonist SHU9119 (Fan et al., 1997). The authors concluded that melanocortinergic neurons exert a tonic inhibition of feeding behavior.
For the history, the point is the role of the molecule. By 1997 the cyclic analog was a pharmacological tool whose agonism could be reversed by a selective antagonist, which is the standard way to attribute an effect to a receptor system. The result is a mouse physiology finding; this page does not extend it beyond that.
A review of the program
Hadley and Dorr reviewed the historical milestones of melanocortin peptide analog development and described how several superpotent, prolonged-acting, enzymatically resistant analogs were designed and synthesized to clarify the nature and role of melanocortins and their receptors (Hadley and Dorr, 2006). The review also describes the patenting and clinical testing of two of these analogs, which is outside the scope of a research-material page and is mentioned only for completeness of the timeline. For the molecules' roles in the lab, the 1980, 1993 and 1997 papers above are the relevant primary sources.
Read together, the sources show an iterative loop typical of chemical biology: an observation about stability, an analog to exploit it, receptors cloned that the analog can label, and then in-vivo use of the analog to ask what the receptors do. The same loop is visible in other peptide families, and the melanotan II overview places it in current terms.
What the history means for current lab use
Three practical points follow. First, MT-2 is a probe compound by origin: its value is that it binds several melanocortin receptor subtypes with high affinity, so selectivity cannot be assumed and subtype-selective controls are needed. Second, the early potency numbers come from specific assays (adenylate cyclase, frog skin, COS-cell binding), so a modern lab should measure its own potency in its own system rather than carry numbers across. Third, because the compound was designed for stability, handling concerns concentrate on chemistry rather than enzymes: see how to reconstitute a lyophilized peptide and the calculator for the arithmetic.
The MT-2 product page lists a 10 mg lyophilized powder, at least 98% HPLC purity, formula C50H69N15O9, stored at 2–8 °C or −20 °C long term and protected from heat, moisture and light. A COA is marked as coming soon on that page, so check it before relying on lot documentation; the COA page explains what such a document contains. Other catalog items are on the shop, and a purity-focused companion is melanotan II purity testing.
| Historical fact | Implication for a lab today |
|---|---|
| Designed as a stable receptor probe | Use it as a probe, with subtype-selective controls |
| Potency measured in frog-skin, adenylate cyclase and COS-cell assays | Measure potency in your own system |
| Binds several cloned subtypes with high affinity | Do not attribute an effect to one receptor without antagonist or knockdown evidence |
| Mouse feeding results used an antagonist reversal | Pair agonist work with a matched antagonist where possible |
Frequently asked questions
Who made the first superpotent alpha-MSH analog?
A 1980 paper by Sawyer and colleagues described [Nle4, D-Phe7]-alpha-MSH as 26 times as potent as alpha-MSH in an adenylate cyclase assay (Sawyer et al., 1980).
Why were norleucine and D-phenylalanine used?
The 1980 work traced prolonged activity of heat-exposed alpha-MSH to racemization at positions 4 and 7 and built analogs that carry those changes; the analog resisted serum enzymes.
When did cyclic analogs appear?
A 1989 paper described the design of a new class of superpotent cyclic alpha-melanotropins based on quenched dynamics simulations (Al-Obeidi et al., 1989).
When were melanocortin receptors cloned?
The first MSH and ACTH receptors were reported in 1992 (Mountjoy et al., 1992); further subtypes followed, including one in 1993 (Chhajlani et al., 1993).
How strongly did the 1980 analog bind the cloned receptors?
In the 1993 cloning study the highest affinity, 5.18 nM, was for NDP-MSH. In 1995 Kd values were 85.1 pM for MC1, 396 pM for MC3 and 5.05 nM for MC5 (Schiöth et al., 1995).
What did the 1997 mouse study show?
Intracerebroventricular MTII inhibited feeding in four hyperphagia models, and the effect was blocked by the antagonist SHU9119 (Fan et al., 1997).
How many melanocortin receptors are there?
Five G protein-coupled melanocortin receptors are described in the 2006 review (Cone, 2006).
Is melanotan II selective for one receptor?
The cited papers do not establish single-receptor selectivity; a lab should use subtype-selective controls.
Are the early potency values transferable to a new assay?
No. They come from specific bioassays and binding systems; each lab should measure potency in its own setup.
What does the product page state?
A 10 mg lyophilized powder, at least 98% HPLC purity, formula C50H69N15O9, stored at 2–8 °C or −20 °C long term, with the COA marked as coming soon.
Responsible research use
Everything on this page is offered for laboratory research use only; it is background reading for qualified researchers, not guidance for any use outside a research setting, and nothing here is a claim about benefit in people or animals. Products from V8 Peptides are sold strictly as research materials: not a drug, food or cosmetic, and not for human or animal consumption. Published studies described here were run by their authors under their own approvals and protocols, and this page does not recommend repeating them.
Related reading: Melanotan II Mechanism: Receptor Binding and cAMP Assays, Reconstituted Melanotan II Stability: Study Design, Melanotan II Reconstitution Math and Study Reporting.
References
- Sawyer TK, Sanfilippo PJ, Hruby VJ, Engel MH, Heward CB, Burnett JB, Hadley ME. 4-Norleucine, 7-D-phenylalanine-alpha-melanocyte-stimulating hormone: a highly potent alpha-melanotropin with ultralong biological activity. Proc Natl Acad Sci U S A. 1980;77(10):5754-5758. doi:10.1073/pnas.77.10.5754
- Al-Obeidi F, Hadley ME, Pettitt BM, Hruby VJ. Design of a new class of superpotent cyclic alpha-melanotropins based on quenched dynamics simulations. J Am Chem Soc. 1989;111(9):3413-3416. doi:10.1021/ja00191a044
- Mountjoy KG, Robbins LS, Mortrud MT, Cone RD. The cloning of a family of genes that encode the melanocortin receptors. Science. 1992;257(5074):1248-1251. doi:10.1126/science.1325670
- Chhajlani V, Muceniece R, Wikberg JES. Molecular cloning of a novel human melanocortin receptor. Biochem Biophys Res Commun. 1993;195(2):866-873. doi:10.1006/bbrc.1993.2125
- Schiöth HB, Muceniece R, Wikberg JES, Chhajlani V. Characterisation of melanocortin receptor subtypes by radioligand binding analysis. Eur J Pharmacol. 1995;288(3):311-317. doi:10.1016/0922-4106(95)90043-8
- Fan W, Boston BA, Kesterson RA, Hruby VJ, Cone RD. Role of melanocortinergic neurons in feeding and the agouti obesity syndrome. Nature. 1997;385(6612):165-168. doi:10.1038/385165a0
- Cone RD. Studies on the physiological functions of the melanocortin system. Endocr Rev. 2006;27(7):736-749. doi:10.1210/er.2006-0034
- Hadley ME, Dorr RT. Melanocortin peptide therapeutics: historical milestones, clinical studies and commercialization. Peptides. 2006;27(4):921-930. doi:10.1016/j.peptides.2005.01.029
